Advertisement
Advertisement

AIDS 2006; Toronto, Canada; August 13-18, 2006

Key Links:

By Topic:

Search:



See Also
Advertisement:
Single-Tablet Regimen for HIV-1
Learn more about the mechanism of action >


UNBP0870 11/14

The Body PRO Covers: The XVI International AIDS Conference

Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART

August 16, 2006

Jesse Raffa, M.Sc., and Harout Tossonian, M.D., and their poster on hepatotoxicity in injection drug users and non-injection drug users.
Jesse Raffa, M.Sc., and Harout Tossonian, M.D., and their poster on hepatotoxicity in injection drug users and non-injection drug users.
Based on data generated in clinical trials and observational cohorts, hepatotoxicity is a known cause of treatment interruption among HIV-infected patients receiving nevirapine (NVP, Viramune)-based highly active antiretroviral therapy (HAART) in up to 10%-15% of cases. This may be especially true for injection drug users (IDUs), who are almost universally coinfected with hepatitis C virus (HCV). With this in mind, the current observational study1 was undertaken to estimate the incidence of hepatotoxicity in HIV-infected IDUs (n = 80) and non-IDUs (n = 82) initiating nevirapine-based HAART as their first non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen.

At baseline, median alanine aminotransferase (ALT) levels were comparable in both groups (39 versus 38 U/L in IDUs and non-IDUs, respectively), while aspartate aminotransferase (AST) levels were slightly higher in IDUs (44 versus 31 U/L), with 94% and 30% of IDUs and non-IDUs, respectively, being coinfected with HCV. Median baseline HIV plasma viral load measures and CD4+ cell counts showed slightly more advanced disease in IDUs (64,750 versus 26,650 copies/mL and 190 versus 290 cells/mm3).

Over 12 months of observation, there was no difference in ALT levels (47 versus 35 U/L in IDUs and non-IDUs, respectively), but there were significantly higher AST levels (53 versus 33 U/L, P < .001) in IDUs. Overall, five-fold increases in ALT or AST were observed in 15% of participants in both groups, with treatment discontinued due to hepatotoxicity in 9% of both groups. Interestingly, the peak incidence of elevation of transaminase levels was observed after one month of therapy in IDUs, but was delayed until the third month in non-IDUs. This suggests that there is a separate pathogenesis for our observations in the two groups. In IDUs, this may be driven by HCV coinfection, and may represent some form of immune reconstitution or HCV re-activation that would resolve on its own even if nevirapine therapy were continued. In non-IDUs, it may be more attributable to nevirapine itself, as this group included patients with higher CD4+ cell counts, a phenomenon that is more common in this population than among IDUs. Using a rigorous statistical model, the factors that were associated with five-fold increases in transaminase levels were HCV coinfection (eight-fold risk), baseline elevation of transaminase levels (three-fold risk) and lack of previous exposure to HAART (four-fold risk).

These results suggest that the majority of HCV coinfected IDUs will not develop hepatotoxicity following the initiation of nevirapine-based HAART. If they do, the mechanism of the elevation of transaminase levels may be different from that previously reported in non-IDUs and may not preclude the continuation of nevirapine therapy once it occurs as it may not relate directly to the drug itself. Therefore, nevirapine should still be considered a viable therapeutic option in this population.

Footnote

  1. Tossonian H, Raffa J, Grebely J, et al. Hepatotoxicity in injection drug users (IDUs) and non-IDUs receiving nevirapine-based HAART. In: Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract WEPE0176.


It is a part of the publication XVI International AIDS Conference.
 



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
Advertisement